Last edition
News about
Senhwa Expands Oncology Manufacturing Focus With CX-5461 - ADC Combination Trial
Senhwa Biosciences, Inc. has announced a significant clinical development milestone with its first-in-class investigational agent Pidnarulex (CX-5461) set to be evaluated in combination with the antibody–drug conjugate trastuzumab deruxtecan (Enhertu) in a phase 1b clinical trial.
Diamyd Medical Advances Type I Diabetes Phase III Efficacy Readout by Nine Months
Diamyd Medical has aligned with the US FDA to accelerate the primary efficacy readout of its Phase 3 DIAGNODE-III trial in type 1 diabetes from 24 to 15 months, enabling results to be available nine months earlier than previously planned.
Harbour BioMed Signs Strategic Collaboration with Lannacheng on Radionuclide Drug Conjugates
Harbour BioMed has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology to jointly advance the development of next-generation radionuclide drug conjugates, combining both companies’ resources and expertise to accelerate innovation in targeted radiopharmaceutical therapies.
Azenta Signs Definitive Agreement to Sell B Medical Systems to Thelema for USD 63 Million
Azenta, Inc., a leading provider of life sciences solutions worldwide, announced that its affiliate, Azenta Germany GmbH, has signed a binding agreement for the sale of Azenta's B Medical Systems business to Thelema S.À R.L., for a purchase price of USD 63 million. The transaction is expected to close on or before March 31, 2026.
S&T Minister Dr Jitendra Singh inaugurates Biotechnology Research and Innovation Council (BRIC)
Union Minister of State (Independent Charge) for Science and Technology (S&T) Dr Jitendra Singh formally inaugurated the Biotechnology Research and Innovation Council (BRIC) Secretariat, on 29 December, by unveiling the inaugural curtain, marking the official opening of a new milestone in India’s biotechnology journey.
Aurobindo Pharma Extends Timeline for Acquisition of Stake in Swarnaakshu Solar Power
Aurobindo Pharma has announced that the completion of its captive solar power purchase agreement and the acquisition of up to a 26 percent stake in Swarnaakshu Solar Power has been deferred to March 31, 2026, due to pending state government approvals for setting up the solar power plant.
Lupin has signed an exclusive licence, supply and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist, strengthening its diabetes portfolio and accelerating its expansion into the obesity treatment segment.
CARsgen Advances Allogeneic CAR-T Manufacturing with Dual IND Filings
CARsgen Therapeutics Holdings Limited announced that it has submitted two separate Investigational New Drug (IND) applications to China’s National Medical Products Administration for its allogeneic BCMA-targeted CAR T-cell therapy, CT0596.
Tiziana Submits Annual Safety Report for Intranasal Foralumab to FDA
Tiziana has submitted its annual safety report for intranasal foralumab to the US FDA, reporting an excellent safety profile based on 37.4 cumulative patient-years of exposure and highlighting the continued need for safer therapies following the FDA’s denial of Sanofi’s tolebrutinib for non-relapsing secondary progressive multiple sclerosis.
Under the agreement, Transcenta will grant EirGenix a non-exclusive licence to use its Highly Intensified Continuous Bioprocessing (HiCB) platform, including highly productive continuous perfusion and integrated hybrid continuous purification process technologies, along with comprehensive process documentation, know-how, and regulatory support packages.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy